PEPG Jumps About +114% in Snapshot as New DM1 Trial Results Arrive
PepGen’s sharp snapshot gain accompanies new DM1 trial data. Small patient numbers, an active U.S. clinical hold and future funding remain important.
Read the story
PepGen’s sharp snapshot gain accompanies new DM1 trial data. Small patient numbers, an active U.S. clinical hold and future funding remain important.
Read the story